Dilini Christina Ranasinghe: The RhD Paradox – D Reactivity with Anti-D
Dilini Christina Ranasinghe, Registrar in Transfusion Medicine at National Blood Centre, shared on LinkedIn:
”The RhD Paradox: D Reactivity with Anti-D.
A 32-year-old primigravida presented at 16 weeks with a remote history of transfusion.
- ABO: O — concordant forward and reverse grouping
- RhD: 2+
- DAT: Negative
- Antibody screen: Positive
- Antibody identified: Anti-D
How can her red cells express D reactivity while her plasma contains anti-D?
- No recent RhIG administration → passive anti-D is unlikely.
- Suspect an alloimmunisation-prone RHD variant, particularly Partial D.
- Partial D red cells may react with routine anti-D reagents while lacking epitopes present on conventional D-positive cells.
Serology demonstrates the phenotype; it does not define the genotype.
The negative DAT supports a circulating alloantibody rather than sensitisation of the patient’s own red cells—but it does not identify the underlying D variant.
Further investigation should include antibody confirmation, repeat RhD characterisation with validated reagents and RHD genotyping, where available. Until resolved, the patient should be managed as RhD negative for transfusion.
If immune anti-D is confirmed, RhIG is not indicated. The pregnancy requires appropriate anti-D quantification or titration and fetal-risk assessment according to local guidelines.
The donor–patient distinction is also critical:
Donors: Any detectable D expression is classified as RhD positive to prevent alloimmunisation in D-negative recipients.
Patients: Unresolved Variant D is managed conservatively as RhD negative until characterised, guiding red-cell selection and RhIG decisions.”

Find more posts featuring Dilini Christina Ranasinghe on Hemostasis Today.
-
Oct 11, 2026, 22:40Bahram Alamdary Badlou: Platelets as First Responders in Hemostasis, Immunity, and Inflammation
-
Oct 11, 2026, 22:22Vipin Singh: New Publication on Hippo-YAP Signaling and Platelet Activation
-
Oct 11, 2026, 22:21Trygve Berge: New AFNOR Paper on AF-related Stroke in Norway
-
Oct 11, 2026, 22:09Omar Alomari: Our New Publication on Apixaban vs Rivaroxaban for VTE
-
Oct 11, 2026, 21:22Shayan Roshan: Happy to Share Two Research Milestones in Trauma Care and Pancreatic Cancer
-
Oct 11, 2026, 21:16Chokri Ben Lamine: Anemia in Myelofibrosis – Multiple Mechanisms, Limited Responses
-
Oct 11, 2026, 21:03Carmela Walker: Supporting Warriors Living With SCD Through Dental Care and Advocacy
-
Oct 11, 2026, 21:00Rishdha Roshad: Intraoperative Cell Salvage – Turning Blood Loss into an Opportunity for Recovery
-
Oct 11, 2026, 20:59Anthony R. Sloan: Honored to Share Our Work at the 20th Midwest Platelet Conference